ClinicalTrials.gg
RecruitingNCT04817618APPEAR-C3GUpdated Nov 5, 2026

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

A Phase 3 interventional study of Placebo and iptacopan in C3G, sponsored by Novartis Pharmaceuticals. Recruiting at 88 sites in 19 countries. Open to participants aged 12 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 3 months later.
Updated Nov 5, 2026Site recruiting status changed3 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
12 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Proteinuria by Novartis — 7 open to participants now, 7 under way, 4 of them phase 3. Proteinuria · Novartis.

Started
2021
with 1 other
Phase 3
5 of 12
4 open now
Registered
5th of 12
by date

Among the 12 studies in Proteinuria by Novartis, this one is one of 2 that started in 2021, is one of 5 in phase 3, and was the 5th registered.

Proteinuria

329 studies on the registry are indexed under Proteinuria; 44 are open to participants now.

Browse Proteinuria studies →

Open to participants now

7 of the 12 studies in Proteinuria by Novartis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 32 Proteinuria studies recruiting now, 12 (38%) set no upper age limit and 16 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 12 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Proteinuria by Novartis, or all of them as a file.
02

Study summary

The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol.

The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.

Read the detailed description

The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to placebo and standard of care in patients with native C3G. CLNP023B12301 is a Phase 3 pivotal trial for registration of iptacopan in C3G. The study aims to determine the reduction in UPCR and improvement in eGFR in participants treated with iptacopan compared to placebo, as well as the proportion of participants who achieve a composite renal endpoint consisting of eGFR and UPCR elements. These effects of iptacopan in conjunction with increases in serum C3 levels will provide support for an iptacopan profile that includes stabilization of eGFR, clinically meaningful reductions in proteinuria and inhibition of the complement AP. Kidney biopsies will be performed in adult participants to evaluate histopathological improvements in immunofluorescence and light microscopy that support these functional benefits of iptacopan.

03

Conditions studied

  • C3G

Browse trials for

Keywords

  • LNP023
  • iptacopan
  • C3G
  • UPCR
  • eGFR
  • proteinuria
  • Quality of life
04

Who can participate

Ages eligible
12 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants age ≥ 12 and ≤ 60 years at screening.
  • Diagnosis of C3G as confirmed by renal within 12 months prior to enrollment in adults and within 3 years in adolescents.
  • Prior to randomization, all participants must have been on a maximally recommended or tolerated dose of an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for at least 90 days. The doses of other antiproteinuric medications including mycophenolic acid, and mineralocorticoid receptor antagonists should be stable for at least 90 days prior to randomization.
  • Reduced serum C3 (defined as less than 0.85 x lower limit of the central laboratory normal range) at Screening.
  • UPCR ≥ 1.0 g/g sampled from the first morning void urine sample at Day -75 and Day -15.
  • Estimated (using the CKD-EPI formula for ages ≥ 18 years and modified Schwartz formula for ages 12 to 17 years) or measured GFR ≥ 30 ml/min/1.73m2 at screening and Day -15.
  • Mandatory vaccination against Neisseria meningitidis and Streptococcus pneumoniae prior to the start of study treatment.
  • If not previously vaccinated or if a booster is required, vaccination against Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to the first study treatment administration. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated.

Exclusion criteria

Exclusion Criteria:

  • Participants who have received any cell or organ transplantation, including a kidney transplantation.
  • Rapidly progressive crescentic glomerulonephritis defined as a 50% decline in the within 3 months with renal findings of glomerular crescent formation seen in at least 50% of glomeruli.
  • Renal biopsy showing interstitial fibrosis/tubular atrophy (IF/TA) of more than 50%
  • Monoclonal gammopathy of undetermined significance (MGUS) confirmed by the measurement of serum free light chains or other investigation as per local standard of care.
  • Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to study treatment administration
  • The presence of fever ≥ 38°C (100.4°F) within 7 days prior to study treatment administration.
  • A history of recurrent invasive infections caused by encapsulated organisms, e.g., N. meningitidis and S. pneumoniae.
  • The use of inhibitors of complement factors (e.g., Factor B, Factor D, C3 inhibitors, anti C5 antibodies, C5a receptor antagonists) within 6 months prior to the Screening visit.
  • The use of (except mycophenolic acids), cyclophosphamide or systemic at a dose >7.5 mg/day (or equivalent for a similar medication) within 90 days of study drug administration.
  • Acute post-infectious glomerulonephritis at screening based upon the opinion of the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    iptacopan 200mg

    iptacopan 200 mg b.i.d.

    Drug: iptacopan

  • Placebo comparator
    Placebo to iptacopan 200mg

    Placebo to iptacopan 200mg b.i.d.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)

  • iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)

    Also known as: LNP023

06

What researchers measure

Primary outcomes

  1. Adult cohort: Log-transformed ratio to baseline in UPCR (sampled from a 24-hour urine collection)

    To demonstrate the superiority of iptacopan compared to placebo in reducing proteinuria at 6 months of treatment.

    Time frame: 6 months (double-blind)

  2. Adolescent cohort: Log-transformed ratio to baseline in UPCR (sampled from a 24-hour urine collection)

    To evaluate the effect of iptacopan on proteinuria at 6 months.

    Time frame: 6 months (double-blind)

  3. Change from baseline in log-transformed UPCR at the 12-month visit (both study treatment arms).

    To evaluate the effect of iptacopan on proteinuria at 12 months.

    Time frame: 12 months (double-blind and open-label)

  4. Change in log-transformed UPCR from the 6-month visit to the 12-month visit in the placebo arm

    To evaluate the effect of iptacopan on proteinuria at 12 months.

    Time frame: From month 6 to month 12 (open-label)

Secondary outcomes

  1. Change from baseline in eGFR.

    To demonstrate the superiority of iptacopan vs. placebo in improving eGFR.

    Time frame: 6 months (double-blind)

  2. Proportion of participants who meet the criteria for achieving a composite renal endpoint

    To demonstrate the superiority of iptacopan vs. placebo in the proportion of participants who meet the criteria for achieving a composite renal endpoint. A participant meets the requirements of the composite renal endpoint if he/she satisfies: (1) a stable or improved eGFR compared to the baseline visit (≤15% reduction in eGFR), and (2) a ≥50% reduction in UPCR compared to the baseline visit.

    Time frame: 6 months (double-blind)

  3. Adult cohort: Change from baseline in disease total activity score in a renal biopsy.

    To demonstrate the effect of iptacopan vs placebo in reducing glomerular inflammation in the kidney.

    Time frame: 6 months (double-blind)

  4. Change from baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) score.

    To assess the effect of iptacopan compared to placebo in improvement of patient reported fatigue.

    Time frame: 6 months (double-blind)

  5. Number of participants with abnormal clinically significant vital signs, ECGs and safety laboratory measurements

    To evaluate the safety and tolerability of iptacopan compared to placebo.

    Time frame: 6 months (double-blind)

  6. Number of participants with study drug discontinuation due to an AE

    To evaluate the safety and tolerability of iptacopan compared to placebo

    Time frame: 6 months (double-blind)

  7. Proportion of participants who meet the criteria for achieving a composite renal endpoint

    To evaluate the effect at 12 months of iptacopan on a composite renal endpoint. A participant meets the requirements of the composite renal endpoint if he/she satisfies: (1) a stable or improved eGFR compared to the baseline visit (≤15% reduction in eGFR), and (2) a ≥50% reduction in UPCR compared to the baseline visit.

    Time frame: 12 months (double-blind and open-label)

  8. Proportion of patients achieving a composite renal endpoint from the 6-month visit to the 12-month visit of the placebo arm

    To evaluate the effect at 12 months of iptacopan on a composite renal endpoint. A participant meets the requirements of the composite renal endpoint if he/she satisfies: (1) a stable or improved eGFR compared to the baseline visit (≤15% reduction in eGFR), and (2) a ≥50% reduction in UPCR compared to the 6 months visit.

    Time frame: month 6, month 12 (open-label)

  9. Change from baseline in the total activity score in a renal biopsy at 12 months

    To evaluate the effect at 12 months of iptacopan in reducing glomerular inflammation in the kidney.

    Time frame: Baseline, month 12 (double-blind and open-label)

  10. Change in the total activity score in a renal biopsy from the 6-month visit to the 12-month visit of the placebo arm.

    To evaluate the effect at 12 months of iptacopan in reducing glomerular inflammation in the kidney.

    Time frame: month 6, month 12 (open-label)

  11. Change from baseline in the FACIT-Fatigue score at 12 months

    To evaluate the effect at 12 months of iptacopan in improvement of patient reported fatigue

    Time frame: Baseline, month 12 (double-blind and open-label)

  12. Change in the FACIT-Fatigue score from the 6-month visit to the 12-month visit of the placebo arm

    To evaluate the effect at 12 months of iptacopan in improvement of patient reported fatigue

    Time frame: month 6, month 12 (open-label)

  13. Number of participants with abnormal clinically significant vital signs, ECGs and safety laboratory measurements

    To evaluate the safety and tolerability of iptacopan during the 6-month open-label treatment period as well as the entire 12- month treatment period

    Time frame: 12 months (double-blind and open-label)

  14. Number of participants with study drug discontinuation due to an AE

    To evaluate the safety and tolerability of iptacopan during the 6-month open-label treatment period as well as the entire 12- month treatment period.

    Time frame: 12 months (double-blind and open-label)

07

Study locations

8 of 88 sites recruiting
  • Childrens Hospital Colorado
    Aurora, Colorado 80045, United States
    Recruiting
  • Nicklaus Childrens Hospital
    Miami, Florida 33155, United States
    Recruiting
  • Georgia Nephrology Research Inst
    Lawrenceville, Georgia 30046, United States
    Completed

    Not enrolling at this site — choose another above.

  • IN University School of Med
    Indianapolis, Indiana 46202-5111, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of Iowa Health Care
    Iowa City, Iowa 52242-1091, United States
    Recruiting
  • University of Iowa Health Care
    Iowa City, Iowa 52242, United States
    Recruiting
    • Nikki Gerot · Contact+1 (319) 335-0348
    • Carla Nester · Principal investigator
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Brigham and Womens Hosp Harvard Med School
    Boston, Massachusetts 02115, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hackensack Uni Medical Center
    Hackensack, New Jersey 07601, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Albany Medical Center
    Albany, New York 12208, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Col Uni Med Center New York Presby
    New York, New York 10032, United States
    Completed

    Not enrolling at this site — choose another above.

  • Baylor Scott and White Research
    Temple, Texas 76502, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of Wisconsin
    Madison, Wisconsin 53792, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Córdoba, Córdoba Province X5016KET, Argentina
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Buenos Aires, W3400ABH, Argentina
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Edegem, 2650, Belgium
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Leuven, 3000, Belgium
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30150-221, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Recife, Pernambuco 50740-900, Brazil
    Recruiting
  • Novartis Investigative Site
    Passo Fundo, Rio Grande do Sul 99010-260, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Joinville, Santa Catarina 89227-680, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Santo André, São Paulo 09090-790, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    São Paulo, São Paulo 04038-002, Brazil
    Recruiting
  • Novartis Investigative Site
    São Paulo, São Paulo 05403-000, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    São Paulo, São Paulo 05403-000, Brazil
    Recruiting
  • Novartis Investigative Site
    Salvador, 40323-010, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    London, Ontario N6A 5W9, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Toronto, Ontario M5G 2C4, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Montreal, Quebec H3T 1C5, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Guangzhou, Guangdong 510080, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Beijing, 100034, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Beijing, 100730, China
    Recruiting
  • Novartis Investigative Site
    Shanghai, 200040, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Prague, 128 08, Czechia
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Lille, 59037, France
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Marseille, 13005, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Montpellier, 34295, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Paris, 75015, France
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Paris, 75019, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50937, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Aachen, 52074, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Erlangen, 91054, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Essen, 45147, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Hamburg, 20246, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Hanover, 30625, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Heidelberg, 69120, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Mainz, 55131, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Athens, 115 27, Greece
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Heraklion Crete., 715 00, Greece
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Thessaloniki, 546 42, Greece
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Thessaloniki, 546 42, Greece
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110017, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110029, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Hyderabad, Telangana 500058, India
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Lucknow, Uttar Pradesh 226014, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Dehradun, Uttarakhand 248001, India
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Petah Tikva, 4920235, Israel
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Petah Tikva, 4941492, Israel
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Ranica, BG 24020, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Milan, MI 20122, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Roma, RM 00165, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Nagoya, Aichi-ken 4668560, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Asahikawa, Hokkaido 0788510, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Sapporo, Hokkaido 0608543, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Takatsuki, Osaka 5691192, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Ōtsu, Shiga 520-2192, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Niigata, 9518520, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Leiden, South Holland 2333 ZA, Netherlands
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Nijmegen, 6525 GA, Netherlands
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Barcelona, Catalonia 08025, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Port de Sagunt, Valencia 46520, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Barcelona, 08035, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Madrid, 28041, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Málaga, 29010, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Seville, 41009, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Bern, 3010, Switzerland
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Lausanne, 1011, Switzerland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Istanbul, Fatih 34093, Turkey (Türkiye)
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Istanbul, Fatih 34098, Turkey (Türkiye)
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Kayseri, Melikgazi 38039, Turkey (Türkiye)
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Ankara, Yenimahalle 06500, Turkey (Türkiye)
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Ankara, Yenimahalle 06500, Turkey (Türkiye)
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Glasgow, Scotland G51 4TF, United Kingdom
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Newcastle upon Tyne, Tyne and Wear NE1 4LP, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    London, WC1N 3JH, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Publications

  • Kavanagh D, Bomback AS, Vivarelli M, Nester CM, Remuzzi G, Zhao MH, Wong EKS, Wang Y, Krishnan I, Schuhmann I, Trapani AJ, Webb NJA, Meier M, Israni RK, Smith RJH; APPEAR-C3G investigators. Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study. Lancet. 2025 Oct 11;406(10512):1587-1598. doi: 10.1016/S0140-6736(25)01148-1. Epub 2025 Sep 25. PubMed 41016405 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Jan 2027, 66 months after the start.

Of 20 phase 3 interventional studies under Proteinuria, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 78. This study's planned 66 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2021
First posted
Mar 26, 2021
StartActual
Jul 28, 2021
Primary completionEst.
Jan 29, 2027
CompletionEst.
Jan 29, 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 2 sites removed. 6 sites changed recruiting status (4 now withdrawn, 2 now completed)
Show 6 sites
  • University of Wisconsin · Madison, United StatesRecruiting→Withdrawn
  • Novartis Investigative Site · Belo Horizonte, BrazilActive, not recruiting→Withdrawn
  • Novartis Investigative Site · Passo Fundo, BrazilRecruiting→Withdrawn
  • Novartis Investigative Site · Salvador, BrazilRecruiting→Withdrawn
  • Novartis Investigative Site · Ranica, ItalyActive, not recruiting→Completed
  • Novartis Investigative Site · Roma, ItalyActive, not recruiting→Completed
Show 3 added (1 Brazil, 1 Japan, 1 Netherlands)
  • Novartis Investigative Site · São Paulo, Brazil
  • Novartis Investigative Site · Ōtsu, Japan
  • Novartis Investigative Site · Nijmegen, Netherlands
Show 2 removed
  • Novartis Investigative Site · Ohtsu, Japan
  • Novartis Investigative Site · Nijmegen, Netherlands
Nov 5, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Nicklaus Childrens Hospital · Miami, United StatesContact J•••@nicklaushealth.org · •••1515→M•••@nicklaushealth.org · •••1515
  • University of Wisconsin · Madison, United StatesContact removed a•••@wisc.edu · •••6020Contact removed (no phone or email listed)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    3 sites added, 2 sites removed. 6 sites changed recruiting status (4 now withdrawn, 2 now completed)
    Show 6 sites
    • University of Wisconsin · Madison, United StatesRecruiting→Withdrawn
    • Novartis Investigative Site · Belo Horizonte, BrazilActive, not recruiting→Withdrawn
    • Novartis Investigative Site · Passo Fundo, BrazilRecruiting→Withdrawn
    • Novartis Investigative Site · Salvador, BrazilRecruiting→Withdrawn
    • Novartis Investigative Site · Ranica, ItalyActive, not recruiting→Completed
    • Novartis Investigative Site · Roma, ItalyActive, not recruiting→Completed
    Show 3 added (1 Brazil, 1 Japan, 1 Netherlands)
    • Novartis Investigative Site · São Paulo, Brazil
    • Novartis Investigative Site · Ōtsu, Japan
    • Novartis Investigative Site · Nijmegen, Netherlands
    Show 2 removed
    • Novartis Investigative Site · Ohtsu, Japan
    • Novartis Investigative Site · Nijmegen, Netherlands
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Nicklaus Childrens Hospital · Miami, United StatesContact J•••@nicklaushealth.org · •••1515→M•••@nicklaushealth.org · •••1515
    • University of Wisconsin · Madison, United StatesContact removed a•••@wisc.edu · •••6020Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04817618
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
Jul 28, 2021
Primary completion
Jan 29, 2027 (estimated)
Completion
Jan 29, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iptacopan

Start the discussion